AbCellera BiologicsABCL +10.81%59 Return-on-Tangible-Equity is -19.92% as of Mar. 2026. GuruFocus rates ABCL with a GF Score™ of 59/100 and a GF Value™ of $5.62 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,202 Biotechnology companies, AbCellera Biologics ranks better than 65.31% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. AbCellera Biologics's annualized net income for the quarter that ended in Mar. 2026 was $-172.66 Mil. AbCellera Biologics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $866.77 Mil. Therefore, AbCellera Biologics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -19.92%.
The historical rank and industry rank for AbCellera Biologics's Return-on-Tangible-Equity or its related term are showing as below:
ABCL'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -20.23 Med: -5.86 Max: 34.27
Current: -16.13
During the past 8 years, AbCellera Biologics's highest Return-on-Tangible-Equity was 34.27%. The lowest was -20.23%. And the median was -5.86%.
ABCL's Return-on-Tangible-Equity is ranked better than 65.31% of 1202
companies
in the Biotechnology industry
Industry Median: -42.435
vs ABCL: -16.13
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
AbCellera Biologics Return-on-Tangible-Equity Related Terms
AbCellera Biologics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for AbCellera Biologics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABCL vs SRPT, RAPP, RXRX: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, AbCellera Biologics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -19.92% mean?
AbCellera Biologics (ABCL) has a Return-on-Tangible-Equity of -19.92% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on AbCellera Biologics and its competitors. According to the industry distribution chart, AbCellera Biologics ranks #417 out of 1202 companies in the Biotechnology industry, placing it in the top 34.7%.
Is AbCellera Biologics' Return-on-Tangible-Equity too high?
AbCellera Biologics' current Return-on-Tangible-Equity is -19.92%. Based on the distribution chart, AbCellera Biologics ranks #417 out of 1202 companies in the Biotechnology industry, which is above the industry midpoint. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Return-on-Tangible-Equity compare to SRPT and RAPP?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #417 out of 1202 companies for Return-on-Tangible-Equity. This puts AbCellera Biologics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on AbCellera Biologics and its competitors. AbCellera Biologics's current Return-on-Tangible-Equity is -19.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.62, compared to a current price of $7.38 — trading 31.3% above its estimated fair value. The current Return-on-Tangible-Equity is -19.92%. AbCellera Biologics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Return-on-Tangible-Equity is -19.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $7.38 is trading 31.3% above its estimated GF Value™ of $5.62.
GuruFocus considers AbCellera Biologics to be Significantly Overvalued.
Key valuation signals for ABCL:
Return-on-Tangible-Equity: -19.92%
GF Value™: $5.62 vs. price of $7.38 (31.3% above fair value)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score
Get the complete analysis for ABCL
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 
